EG00229 (trifluoroacetate)

EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2[1].

Product Specifications

CAS Number

[1210945-69-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Complement System

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/EG00229.html

Purity

98.03

Solubility

DMSO : ≥ 41.4 mg/mL

Smiles

N=C(N)NCCC[C@@H](C(O)=O)NC(C1=C(NS(=O)(C2=CC=CC3=NSN=C32)=O)C=CS1)=O.O=C(O)C(F)(F)F

Molecular Formula

C19H20F3N7O7S3

Molecular Weight

611.60

Precautions

H302, H315, H319

References & Citations

[1]Jarvis A, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53 (5) :2215-26.|[2]Grun D, et al. VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors. Oncogene. 2016 Aug 18;35 (33) :4379-87.